PE20221006A1 - Compuestos antibacterianos para el tratamiento de la enfermedad de la bacteriana por "enterobacteriaceae" - Google Patents

Compuestos antibacterianos para el tratamiento de la enfermedad de la bacteriana por "enterobacteriaceae"

Info

Publication number
PE20221006A1
PE20221006A1 PE2022000118A PE2022000118A PE20221006A1 PE 20221006 A1 PE20221006 A1 PE 20221006A1 PE 2022000118 A PE2022000118 A PE 2022000118A PE 2022000118 A PE2022000118 A PE 2022000118A PE 20221006 A1 PE20221006 A1 PE 20221006A1
Authority
PE
Peru
Prior art keywords
group
phenyl
alkyl
enterobacteriaceae
treatment
Prior art date
Application number
PE2022000118A
Other languages
English (en)
Spanish (es)
Inventor
Paul Meo
Mohammed Nawaz Khan
Cedric Charrier
Original Assignee
Discuva Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60664899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20221006(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Discuva Ltd filed Critical Discuva Ltd
Publication of PE20221006A1 publication Critical patent/PE20221006A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Warehouses Or Storage Devices (AREA)
PE2022000118A 2017-11-03 2018-11-02 Compuestos antibacterianos para el tratamiento de la enfermedad de la bacteriana por "enterobacteriaceae" PE20221006A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1718285.8A GB201718285D0 (en) 2017-11-03 2017-11-03 Antibacterial Compounds
PCT/GB2018/053183 WO2019086890A1 (en) 2017-11-03 2018-11-02 Antibacterial compounds

Publications (1)

Publication Number Publication Date
PE20221006A1 true PE20221006A1 (es) 2022-06-15

Family

ID=60664899

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2022000118A PE20221006A1 (es) 2017-11-03 2018-11-02 Compuestos antibacterianos para el tratamiento de la enfermedad de la bacteriana por "enterobacteriaceae"
PE2020000454A PE20211390A1 (es) 2017-11-03 2018-11-02 Compuestos antibacterianos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2020000454A PE20211390A1 (es) 2017-11-03 2018-11-02 Compuestos antibacterianos

Country Status (23)

Country Link
US (2) US11345694B2 (enExample)
EP (2) EP4606375A3 (enExample)
JP (2) JP7348897B2 (enExample)
KR (1) KR102470319B1 (enExample)
CN (1) CN111566099B (enExample)
AU (1) AU2018361828B2 (enExample)
BR (1) BR112020008531A2 (enExample)
CA (1) CA3081423A1 (enExample)
CL (2) CL2020001147A1 (enExample)
CO (1) CO2020005420A2 (enExample)
EA (1) EA202091118A1 (enExample)
ES (1) ES3005164T3 (enExample)
GB (1) GB201718285D0 (enExample)
GE (1) GEP20237522B (enExample)
IL (1) IL274229B2 (enExample)
MA (1) MA50504A (enExample)
MX (2) MX2020004562A (enExample)
NZ (1) NZ764310A (enExample)
PE (2) PE20221006A1 (enExample)
SG (1) SG11202003717UA (enExample)
UA (1) UA128475C2 (enExample)
WO (1) WO2019086890A1 (enExample)
ZA (1) ZA202002093B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201718285D0 (en) * 2017-11-03 2017-12-20 Discuva Ltd Antibacterial Compounds
CR20200553A (es) 2018-04-18 2021-04-08 Constellation Pharmaceuticals Inc Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
EP3797108B1 (en) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
CN111635372B (zh) * 2020-06-28 2022-05-27 齐鲁工业大学 一种恶唑酮衍生物及其合成方法
JP2024517233A (ja) * 2021-05-03 2024-04-19 ディスキューバ リミテッド 抗菌化合物の調製のための方法
WO2023157628A1 (ja) 2022-02-21 2023-08-24 三井化学株式会社 金属部材、金属樹脂接合体及び金属部材の製造方法
CN120208965B (zh) * 2025-05-28 2025-08-12 四川大学 靶向革兰氏阴性菌外膜组装关键蛋白质机器的4-(吡啶-4-基)-1h-咪唑-2-胺类衍生物、组合物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA869348B (en) 1985-12-12 1987-10-28 Smithkline Beckman Corp Inhibition of the 5-lipoxygenase pathway
US4780470A (en) * 1986-08-19 1988-10-25 Smithkline Beckman Corporation Inhibition of interleukin-1 by monocytes and/or macrophages
JP2808460B2 (ja) * 1989-11-16 1998-10-08 大正製薬株式会社 イミダゾール誘導体
JPH09124640A (ja) 1995-08-25 1997-05-13 Nippon Soda Co Ltd ピリジルイミダゾール化合物、製法および農園芸用殺菌剤
US6207687B1 (en) 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
CO5271680A1 (es) 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
WO2004005264A2 (en) * 2002-07-05 2004-01-15 Axxima Pharmaceuticals Ag Imidazole compounds for the treatment of hepatitis c virus infections
JP2004196678A (ja) 2002-12-17 2004-07-15 Dainippon Pharmaceut Co Ltd ピラゾール系誘導体
AU2004289539C1 (en) 2003-11-14 2012-06-07 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
CA2556944C (en) * 2004-03-05 2012-10-09 Taisho Pharmaceutical Co., Ltd. Thiazole derivative
JP2007277230A (ja) * 2006-03-15 2007-10-25 Tanabe Seiyaku Co Ltd 医薬組成物
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
WO2011080132A2 (en) * 2009-12-17 2011-07-07 Katholieke Universiteit Leuven, K.U. Leuven R&D Compounds, compositions and methods for controlling biofilms
GB201016261D0 (en) 2010-09-28 2010-11-10 Univ Leuven Kath Compounds for controlling biofilms and process for their production
WO2012135016A2 (en) 2011-03-25 2012-10-04 North Carolina State University Inhibition of bacterial biofilms and microbial growth with imidazole derivatives
KR101938368B1 (ko) 2011-07-13 2019-01-14 주식회사 티움바이오 Alk5 및/또는 alk4 억제제로서의 2-피리딜-치환된 이미다졸
US8840912B2 (en) 2012-01-09 2014-09-23 North Carolina State University Imidazole derivatives useful for controlling microbial growth
US10456440B2 (en) 2014-05-16 2019-10-29 Atriva Therapeutics Gmbh Anti-infective strategy against influenza virus and S. aureus coinfections
US9884868B2 (en) 2015-03-02 2018-02-06 Rigel Pharmaceuticals, Inc. TGF-beta inhibitors
US20180044316A1 (en) 2015-03-05 2018-02-15 University Of Notre Dame Du Lac Potentiators of beta-lactam antibiotics
CA3030582A1 (en) 2015-07-22 2017-01-26 The Royal Institution For The Advancement Of Learning/Mcgill University Compounds and uses thereof in the treatment of cancers and other medical conditions
GB201718285D0 (en) * 2017-11-03 2017-12-20 Discuva Ltd Antibacterial Compounds

Also Published As

Publication number Publication date
GEP20237522B (en) 2023-08-10
EP4606375A3 (en) 2025-11-19
MX2021010246A (es) 2021-09-21
IL274229B2 (en) 2023-05-01
AU2018361828A1 (en) 2020-05-28
EP3704105B9 (en) 2025-03-05
IL274229A (en) 2020-06-30
WO2019086890A1 (en) 2019-05-09
EP3704105B1 (en) 2024-10-16
NZ764310A (en) 2023-04-28
CL2021002263A1 (es) 2022-04-01
AU2018361828B2 (en) 2023-05-18
MA50504A (fr) 2020-09-09
JP2022025116A (ja) 2022-02-09
CL2020001147A1 (es) 2020-08-14
US20210163460A1 (en) 2021-06-03
EA202091118A1 (ru) 2020-08-06
ZA202002093B (en) 2023-11-29
CN111566099A (zh) 2020-08-21
ES3005164T3 (en) 2025-03-14
GB201718285D0 (en) 2017-12-20
SG11202003717UA (en) 2020-05-28
MX2020004562A (es) 2020-08-13
KR102470319B1 (ko) 2022-11-25
KR20200084875A (ko) 2020-07-13
IL274229B1 (en) 2023-01-01
JP7348897B2 (ja) 2023-09-21
JP2021501756A (ja) 2021-01-21
BR112020008531A2 (pt) 2020-10-20
CN111566099B (zh) 2023-06-02
PE20211390A1 (es) 2021-07-27
CO2020005420A2 (es) 2020-07-31
ES3005164T9 (en) 2025-03-24
EP3704105A1 (en) 2020-09-09
US20220372027A1 (en) 2022-11-24
CA3081423A1 (en) 2019-05-09
EP4606375A2 (en) 2025-08-27
UA128475C2 (uk) 2024-07-24
US11345694B2 (en) 2022-05-31

Similar Documents

Publication Publication Date Title
PE20221006A1 (es) Compuestos antibacterianos para el tratamiento de la enfermedad de la bacteriana por "enterobacteriaceae"
EA202092896A1 (ru) Гетероциклические и гетероарильные соединения для лечения болезни гентингтона
EA202091484A1 (ru) 4-азаиндольные соединения
EA202091480A1 (ru) Аминоиндольные соединения, пригодные в качестве ингибиторов tlr
EA202091477A1 (ru) Замещенные соединения простых индольных эфиров
CY1120834T1 (el) Δικυκλικες αζωτουχες ενωσεις ως αγωνιστες μουσκαρινικων υποδοχεων μ1
PE20091381A1 (es) Inhibidores del virus de la hepatitis c
PE20191541A1 (es) Composiciones y metodos para inhibir la accion de la arginasa
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
CL2018000292A1 (es) Compuestos farmacéuticos
CO2017004481A2 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
AR083367A1 (es) Compuestos de tipo quinazolinona como antagonistas de crth
ES2770058T3 (es) Compuestos y composiciones destinados a modular las actividades de quinasa de EGFR mutante
PE20170127A1 (es) Indazol-3-carboxamidas 5-sustituidas y preparacion y uso de las mismas
UY32859A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
EA201500557A1 (ru) Антигельминтные соединения, композиции и способы их применения
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
PE20091005A1 (es) N-(2-(hetaril)aril)arilsulfonamidas y n-(2-(hetaril)hetaril)arilsulfonamidas
PE20151781A1 (es) Piridonamidas como moduladores de canales de sodio
PE20160869A1 (es) Derivados novedosos de amino pirimidina
PE20090435A1 (es) Inhibidores de tetrahidropiranocromeno de gamma secretasa
MX375153B (es) Compuestos antihelminticos.
CL2020002157A1 (es) Derivados de triazina para el tratamiento de enfermedades relacionadas con neurotrofinas.
CY1123494T1 (el) Enωσeiς etepoapyλo-kapboξamiδioy ως anaσtoλeiς thς ripk2
CY1124795T1 (el) Συνθεσεις και μεθοδοι για τη θεραπεια και προφυλαξη λοιμωξεων χειρουργικης θεσης